TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.0510nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.0810nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.150nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.190nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.210nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.230nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.240nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.240nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.340nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.350nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.360nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.370nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.510nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.830nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.850nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.850nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.970nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.30nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.80nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 3.30nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 5.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 7.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 7.80nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 8.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.00E+3nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132C mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132G mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132C mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human Myc-DDK-tagged IDH1 R132C mutant using alpha-ketoglutarate as substrate preincubated for 15 mins followed by substrat...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132L mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132G mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by rapidfire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IDH1 R132C mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human Myc-DDK-tagged IDH1 R132H mutant using alpha-ketoglutarate as substrate preincubated for 15 mins followed by substrat...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human Myc-DDK-tagged IDH1 R132H mutant using alpha-ketoglutarate as substrate preincubated for 15 mins followed by substrat...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by rapidfire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132S mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by rapidfire hi...More data for this Ligand-Target Pair